Blood Flow Path Reconstruction in Rectal Cancer

Surgery Clinical Trial

Official title:

Blood Flow Path Reconstruction in Rectal Cancer After High IMA Ligation Through Preoperative and Postoperative Comparison by Manual Subtraction CTA

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05674097
• Other study ID #: 2020GQliu
• Status: Completed
• Start date: June 8, 2020
• Est. completion date: March 31, 2022

Study information

• Verified date: December 2022
• Source: Shandong First Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

89 patients with distal sigmoid and rectal cancer were referred in our observation and underwent MS-CTA between June 2020 and March 2022. We classified the distribution of LCA and confirmed whether there exists AMCA (accessory middle colic artery). Then we planned blood flow path based on the classification of LCA branches before operation. High ligation was applied in regular radical surgery. During operation, we carefully protect the bifurcation of ascending and descending LCA. Then we compared the planned blood flow path with the actual postoperative blood flow path to verify the mechanism we proposed previously.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 89
• Est. completion date: March 31, 2022
• Est. primary completion date: March 8, 2022
• Gender: All
• Age group: 39 Years to 81 Years

Eligibility

Inclusion Criteria:

• (1) patients with distal sigmoid colon and rectal cancer; (2) cTNM stage was confirmed to be I-III on MRI or CT; (3) Laparoscopic anterior resection (LAR) was performed.

Exclusion Criteria:

• (1) The starting time of arterial phase scanning is earlier; (2) The anatomic structure is not clear; (3) No enhanced CT after operation (only 5 cases).

Related Conditions & MeSH terms

• Image
• Rectal Cancer
• Rectal Neoplasms
• Surgery

Intervention

Other:
• no intervention
no intervention

Locations

Country	Name	City	State
China	Guoqin LIU	Jinan	Shandong

Sponsors (2)

Lead Sponsor	Collaborator
Guoqin LIU	Jinan Central Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Six pattens of blood flow and AMCA based on the preoperative observation		1 hour